<DOC>
	<DOCNO>NCT03051061</DOCNO>
	<brief_summary>The optimal antithrombotic treatment Coronary Heart disease ( CHD ) patient combine Atrial Fibrillation ( AF ) hotspot present . Although European American guideline give hand u , absence solid evidence-based data safety antithrombotic therapy Asian population . Only clinical trial registry available guide difficult clinical decision making patient combine AF CHD，the investigator highlight need rapid development clinical trial close large gap evidence . This research aim know real-world use antithrombotic treatment clinical prognosis Coronary Heart Disease patient complicate Atrial Fibrillation .</brief_summary>
	<brief_title>Effect Antithrombotic Treatment Patients With Both Coronary Heart Disease Atrial Fibrillation</brief_title>
	<detailed_description>1 . Our study observational , retrospective Study . 2 . Key date element definition variable line American Heart Association ( AHA ) /European Society Cardiology ( ECS） recommendation AF CHD . To reflect contemporary antithrombotic management AF CHD past five year , follow data collect : basic socio-demographic information , symptom sign relate AF , medical history , result physical examination laboratory test . 3 . Follow-up time least 12 month . The patient ask medication clinical outcome telephone interview outpatient clinic . Then analyze relative safety efficacy various antithrombotic regimen . 4 . Based large retrospective study Karjalainen address issue , anticipate 30 % incidence composite outcome triple therapy arm . To achieve precision 10 % α=0.05 rate defaulter 10 % . The final sample size estimate 986 . 5 . Henan institute cardiology epidemiology responsible design , date quality control statistical analysis .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1 . Patients chest pain significant lesion &gt; 50 % angiographically . 2 . Patients document AF confirm 12 lead ECG Holter ECG . 1 . Rheumatic valvular disease . 2 . Contraindications oral anticoagulation . 3 . Combined serious disease life expectancy &lt; 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>antithrombotic treatment</keyword>
	<keyword>clinical prognosis</keyword>
</DOC>